drugset / Trial / NCT05663710
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
Phase 1/2
Suspended
100 enrolled
M.D. Anderson Cancer Center
Telix Pharmaceuticals (Innovations) Pty Limited · collabUnited States Department of Defense · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).
Timeline
- Start
- 2023-06-30
- Primary completion
- 2027-10-30
- Completion
- 2027-10-30
Outcome
Outcome not reported
Stopped: “PI requested”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu girentuximab | Unknown | — | Intravenous |
| Subject | Cabozantinib | Small molecule | — | Oral |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Background | ArabinoFuranosylGuanine [18F]F-AraG | Diagnostic / imaging agent | — | Intravenous |